JAAHA Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Novosad, C. A.
Right arrow Articles by Gieger, T. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Novosad, C. A.
Right arrow Articles by Gieger, T. L.
Journal of the American Animal Hospital Association 42:110-120 (2006)
© 2006 American Animal Hospital Association

Retrospective Study

Retrospective Evaluation of Adjunctive Doxorubicin for the Treatment of Feline Mammary Gland Adenocarcinoma: 67 Cases

C. Andrew Novosad, DVM, Philip J. Bergman, DVM, PhD, Diplomate ACVIM, Maura G. O’Brien, DVM, Diplomate ACVS, Joanne A. McKnight, DVM, Diplomate ACVIM, Sarah C. Charney, DVM, Diplomate ACVIM, Kim A. Selting, DVM, Diplomate ACVIM, Joanne C. Graham, DVM, Diplomate ACVIM, Stephanie S. Correa, DVM, Diplomate ACVIM, Mona P. Rosenberg, DVM, Diplomate ACVIM and Tracy L. Gieger, DVM, Diplomate ACVIM

From the Donaldson-Atwood Cancer Clinic and Flaherty Comparative Oncology Laboratory (Novosad, Bergman, McKnight, Charney), The Animal Medical Center, 510 East 62nd Street, New York, New York 10021; VCA West Los Angeles Animal Hospital (O’Brien), 1818 South Sepulveda Boulevard, Los Angeles, California 90025; The Department of Clinical Sciences (Selting), College of Veterinary Medicine, Colorado State University, Fort Collins, Colorado 80523; The Department of Clinical Sciences (Graham), School of Veterinary Medicine, Iowa State University, Ames, Iowa 50011-1250; Veterinary Specialists of South Florida (Correa), 9410 Stirling Road, Cooper City, Florida 33024; Veterinary Cancer Referral Group (Rosenberg), 11300 West Olympic Boulevard #120, Los Angeles, California 90064; The Veterinary Medical Teaching Hospital (Gieger), School of Veterinary Medicine, University of California, Davis, California 95616.

Medical records for 67 cats with histologically confirmed mammary gland adenocarcinomas treated with adjunctive doxorubicin from June 1994 through December 2002 were reviewed. Data were examined to evaluate factors influencing disease-free interval (DFI) and survival time. The Kaplan-Meier median survival time of cats that received surgery and doxorubicin was 448 days. The Kaplan-Meier median DFI was 255 days. Significant univariate prognostic factors for DFI included histological subtype, completion of initial chemotherapy, development of metastatic disease, and location of metastatic disease. Significant univariate prognostic factors for survival included tumor volume, the development of metastatic disease, and location of metastatic disease.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the American Animal Hospital Association.